期刊文献+

晚期慢性肾脏病患者骨质疏松症的治疗研究进展

Research progress on the treatment of osteoporosis in patients with advanced chronic kidney disease
原文传递
导出
摘要 骨质疏松症是慢性肾脏病(CKD)患者常见的并发症之一,严重影响患者的生存质量及增加病死率。抗骨质疏松药物根据作用机理不同,主要分为骨吸收抑制剂和骨形成促进剂两大类。晚期CKD患者应用抗骨质疏松药物时更容易出现不良反应、增加CKD进展风险。本文综述了晚期CKD患者骨质疏松症的治疗研究进展,以期为临床工作提供帮助。 Osteoporosis is one of the common complications of patients with chronic kidney disease (CKD), and can seriously affect the patients’ quality of life and increase the mortality. According to their mechanisms of action, the anti-osteoporosis drugs are mainly divided into bone resorption inhibitors and osteoanabolic agents. Patients with advanced CKD are more likely to experience adverse effects of anti-osteoporosis drugs, and may have an increased risk of CKD progression. This article reviewed the progress of research on the treatment of osteoporosis in patients with advanced CKD, aiming to provide assistance for clinical work.
作者 肖伍豪 刘抗寒 Wuhao Xiao;Kanghan Liu(Department of Nephrology,Hunan Provincial People′s Hospital/First Hospital Affiliated to Hunan Normal University,Changsha 410005,Hunan Province,China)
出处 《中华肾病研究电子杂志》 2024年第2期92-96,共5页 Chinese Journal of Kidney Disease Investigation(Electronic Edition)
基金 湖南省自然科学基金项目(2020JJ4405) 湖南省卫生健康委项目(202103051068)。
关键词 晚期慢性肾脏病 骨质疏松症 药物治疗 Advanced chronic kidney disease Osteoporosis Treatment
  • 相关文献

参考文献10

二级参考文献81

  • 1曹芙萍.降钙素药理与临床应用进展[J].安徽医药,2006,10(10):777-779. 被引量:3
  • 2Moe SM, Drueke T, Lameire N, et al. Chronic kidney disease-mineral-bone disorder: a new paradigm. Adv Chronic Kidney Dis, 2007,14: 3-12.
  • 3Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol, 2004, 15: 2208-2218.
  • 4Friedman EA. Calcium-based phosphate binders appropriate in chronic renal failure. Clin J Am Soc Nephrol, 2006. 1: 704-709.
  • 5Kovesdy CP, Mehrotra R, Kalantar-Zadeh K. Battleground: chronic kidney disorders mineral and bone disease-calcium obsession, vitamin d, and binder confusion. Clin J Am Soc Nephrol, 2008, 3: 168-173.
  • 6Johansen KL, Chertow GM. Chronic kidney disease mineral bone disorder and health-related quality of life among incident end-stage renal-disease patients. J Ren Nutr, 2007,17: 305-313.
  • 7Eknoyan G, Lameire N, Barsoum R, et al. The burden of kidney disease: improving global outcomes. Kidney Int, 2004, 66: 1310-1314.
  • 8Chung SY, Chen TH, Lai SL, et al. Hypercalcemia and status epilepticus relates to salmon calcitonin administration in breast cancer. Breast, 2005, 14: 399-402.
  • 9Liu RH, Werth VP. What is new in the treatment of steroid-induced osteoporosis? Semin Cutan Med Surg, 2007, 26: 203-209.
  • 10Stroup J, Kane MP, Abu-Baker AM. Teriparatide in the treatment of osteoporosis. Am J Health Syst Pharm, 2008, 65: 532-539.

共引文献1693

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部